Quarterly infographic: MRSA, MSSA and Gram-negative bacteraemia and CDI, data up to July to September 2025
Updated 22 January 2026
Applies to England
Gram-negative bacteraemias (E. coli, Klebsiella spp. and P. aeruginosa)
Pseudomonas aeruginosa (P. aeruginosa) bacteraemia
July to September 2024: 8.6 people out of every 100,000 developed a P. aeruginosa bacteraemia.
July to September 2025: in England, 9.2 people out of every 100,000 developed a P. aeruginosa bacteraemia.
Klebsiella species (spp.) bacteraemia
July to September 2024: 25.1 out of every 100,000 persons developed a Klebsiella spp. bacteraemia.
July to September 2025: 26.4 out of every 100,000 persons developed a Klebsiella spp. bacteraemia.
Escherichia coli (E. coli) bacteraemia
July to September 2024: 79.4 out of every 100,000 persons developed an E. coli bacteraemia.
July to September 2025: 84.4 out of every 100,000 persons developed an E. coli bacteraemia.
Staphylococcus aureus (S. aureus) MRSA and MSSA bacteraemia and Clostridioides difficile (C. difficile) infections
Meticillin-resistant Staphylococcus aureus (MRSA) bacteraemia
July to September 2024: 1.8 out of every 100,000 persons developed an MRSA bacteraemia.
July to September 2025: 2.0 out of every 100,000 persons developed an MRSA bacteraemia.
Meticillin-susceptible Staphylococcus aureus (MSSA) bacteraemia
July to September 2024: 23.7 out of every 100,000 persons developed an MSSA bacteraemia.
July to September 2025: 23.8 out of every 100,000 persons developed an MSSA bacteraemia.
Clostridioides difficile (C. difficile) infection
July to September 2024: 37.1 out of every 100,000 persons developed a C. difficile infection.
July to September 2025: 32.3 out of every 100,000 persons developed a C. difficile infection.